查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949584

基因檢測市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、應用、產品、通路、最終用戶、地區和競爭格局分類，2021-2031年）

Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By Product, By Channel, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因檢測市場預計將從 2025 年的 93.1 億美元成長到 2031 年的 185.8 億美元，複合年成長率達到 12.21%。

該領域涉及對人類DNA、RNA、染色體、蛋白質和代謝物進行實驗室分析，以檢測與體細胞或遺傳疾病相關的基因型、突變和表現型。成長要素的關鍵因素包括全球慢性病盛行率的上升以及對個人化醫療日益成長的需求，而這需要識別準確的生物標記以最佳化治療。美國癌症協會（ACS）預測，到2025年，美國將新增超過200萬例癌症病例，這意味著龐大的患者群體需要進行基因組分析以製定有效的治療方案。

市場概覽
預測期 2027-2031
市場規模：2025年 93.1億美元
市場規模：2031年 185.8億美元
複合年成長率：2026-2031年 12.21%
成長最快的細分市場 次世代定序
最大的市場 北美洲

儘管潛力巨大，但市場仍面臨著充滿挑戰且不斷變化的法規環境。檢查室自建檢測（LDT）的報銷政策不一致，監管框架也不夠明確，這可能會阻礙新型診斷檢測方法的開發和商業化。這些監管障礙往往導致核准時間延長、合規成本增加，從而限制患者獲得先進檢測方案的機會，並阻礙現有和新興市場參與者的收入成長。

市場促進因素

腫瘤學領域基因檢測的擴展是推動市場發展的關鍵因素，其主要驅動力來自精準醫療的轉型和伴隨診斷的需求。隨著製藥公司推出標靶治療，對基因組分析以識別合格的患者的需求迅速成長，直接推動了診斷服務提供者檢測量的成長。新治療方法的核准進一步強化了這一趨勢。根據 PharmaBoardroom 於 2025 年 5 月發布的報告，FDA 在 2024 年核准了七種新的細胞和基因療法，顯著提升了對精準基因檢測的需求。液態生物檢體和分子診斷領域的公司正經歷著快速成長。例如，Guardant Health 報告稱，在其截至 2025 年 10 月的會計年度中，其臨床腫瘤檢測量年增 40%，達到約 74,000 例。

同時，非侵入性產前檢測 (NIPT) 的日益普及正將市場範圍從腫瘤學擴展到生殖醫學。無細胞 DNA 染色體異常篩檢的廣泛接受度正在革新產前護理，促使醫療服務提供者將這些安全、高通量的解決方案納入常規診療流程。這種普及體現在各大實驗室的營運規模上，它們正在處理創紀錄數量的檢體。 2025 年 11 月，Neatara 報告稱，其第三季度處理了約 893,600 份檢測樣本，比去年同期成長 15.2%，這凸顯了臨床和生殖健康保健領域對基因篩檢的強烈依賴和日益成長的趨勢。

市場挑戰

複雜多變的監管環境和不一致的報銷政策對全球基因檢測市場的擴張構成了重大障礙。這種環境為實驗室帶來了不確定性，因為嚴格的合規要求延長了核准流程，尤其對於檢查室自建檢測（LDT）更是如此。支付方監管不力且嚴格的報銷限制顯著增加了診斷服務提供者的行政負擔。這些障礙扼殺了創新，阻礙了新型檢測方法的商業化。企業面臨營運成本上升和收入延遲到帳的困境，而官僚主義的障礙也使得將個人化醫療的需求轉化為實際檢測量變得困難。

近期數據證實了這些醫保覆蓋障礙的實際影響：美國醫學會 (AMA) 2024 年的報告顯示，94% 的受訪醫生表示，事先核准流程會延誤患者獲得治療。這種行政上的繁瑣程序會延長診斷時間，並常常導致檢測中止，從而直接減少基因組分析的實施數量，並限制市場參與企業的收入潛力。

市場趨勢

將人工智慧 (AI) 和機器學習 (ML) 整合到基因組數據分析中，正在從根本上改變市場運作方式。隨著定序通量的提高，產生的數據量已超過人工分析能力，因此自動化解決方案對於變異分類和解讀至關重要。這項技術使實驗室能夠擴展其生物資訊流程，同時加快週轉時間並提高複雜報告的準確性。這種應用的商業性價值顯而易見。在英偉達 (NVIDIA) 於 2025 年 7 月發布的題為「醫療保健和生命科學領域人工智慧現狀：2025 年趨勢」的調查中，超過 80% 的醫療保健和生命科學專業人士表示，人工智慧促進了其所在機構的收入成長，凸顯了計算工具對財務績效的重要性。

同時，針對健康人群的預防性基因組篩檢正在將市場拓展至症狀患者之外。醫療系統正從被動診斷轉向主動人群健康管理，利用大規模定序在症狀出現之前檢測出遺傳性癌症、心血管疾病和其他疾病的風險因素。支持這一轉變的是將基因組學見解融入基層醫療的大型跨機構合作。例如，2025年2月，TriHealth宣布與Helix合作，啟動一項精準人群健康管理舉措，目標是在五年內覆蓋10萬名參與者，這展現了預防性基因數據的規模化應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球基因檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按技術（次世代定序、晶片技術、基於PCR的檢測）
    • 按用途分類（祖籍與民族、性狀篩檢、遺傳疾病帶原者狀態、新生兒篩檢、健康與保健 - 傾向/風險/易感性）
    • 依產品分類（耗材、設備、軟體及服務）
    • 依銷售管道（線上、線下）
    • 依最終使用者（醫院/診所、診斷檢查室、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲基因檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球基因檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • 24Genetics SL
  • Prenetics Global Limited
  • Circle DNA
  • TellmeGen
  • 23andMe, Inc.
  • AncestryDNA
  • myDNA Life Australia Pty Ltd.
  • Myriad Genetics, Inc.
  • MapmyGenome
  • MyHeritage Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24371

The Global Genetic Testing Market is projected to expand from USD 9.31 Billion in 2025 to USD 18.58 Billion by 2031, achieving a compound annual growth rate of 12.21%. This sector involves the laboratory analysis of human DNA, RNA, chromosomes, proteins, or metabolites to detect genotypes, mutations, or phenotypes associated with somatic or heritable conditions. Key growth drivers include the rising global prevalence of chronic disorders and the increasing demand for personalized medicine, which requires precise biomarker identification for tailored treatments. According to the American Cancer Society, projections for 2025 estimated over 2 million new cancer diagnoses in the United States, indicating a vast patient pool necessitating genomic profiling for effective treatment planning.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 9.31 Billion
Market Size 2031USD 18.58 Billion
CAGR 2026-203112.21%
Fastest Growing SegmentNext Generation Sequencing
Largest MarketNorth America

Despite this potential, the market contends with a challenging and shifting regulatory environment. Inconsistent reimbursement policies and ambiguous oversight frameworks for Laboratory Developed Tests can hinder the creation and commercialization of new diagnostic assays. These regulatory barriers often lead to prolonged approval times and higher compliance costs, restricting patient access to advanced testing solutions and limiting revenue growth for both established and emerging market players.

Market Driver

The growing use of genetic testing in oncology is a major market force, driven by the shift toward precision medicine and the necessity for companion diagnostics. As pharmaceutical companies introduce targeted therapies, the need for genomic profiling to identify eligible patients has surged, directly increasing test volumes for diagnostic providers. This trend is reinforced by the approval of new treatments; PharmaBoardroom noted in May 2025 that the FDA approved seven new cell and gene therapies in 2024, creating significant demand for precise genetic assays. Companies in liquid biopsy and molecular diagnostics are seeing utilization spikes; for example, Guardant Health's October 2025 financial results reported a 40% year-over-year increase in clinical oncology test volumes, reaching approximately 74,000 tests.

Simultaneously, the rising adoption of Non-Invasive Prenatal Testing (NIPT) is extending market reach beyond oncology into reproductive health. The broad acceptance of cell-free DNA screening for chromosomal abnormalities has revolutionized prenatal care, prompting providers to make these safe, high-throughput solutions a routine part of practice. This adoption is reflected in the scale of operations at leading laboratories, which are handling record sample numbers. Natera reported in November 2025 that it processed roughly 893,600 tests during the third quarter, a 15.2% increase from the prior year, highlighting the strong and increasing reliance on genetic screening for clinical and reproductive needs.

Market Challenge

A complex and evolving regulatory landscape, along with inconsistent reimbursement policies, creates a significant barrier to the Global Genetic Testing Market's expansion. This environment generates uncertainty for laboratories, especially regarding Laboratory Developed Tests, by enforcing strict compliance requirements that lengthen approval timelines. When oversight is unclear or payers apply rigid coverage restrictions, the administrative burden on diagnostic providers grows substantially. These obstacles stifle innovation and deter the commercialization of new assays, as companies face increased operational costs and delayed revenue, causing the market to struggle in converting the demand for personalized medicine into actual testing volumes due to bureaucratic impediments.

Recent data confirms the operational impact of these coverage barriers. In 2024, the American Medical Association reported that 94% of surveyed physicians experienced delays in patient access to care due to prior authorization processes. Such administrative friction prolongs diagnosis times and often results in test abandonment, directly lowering the number of genomic profiles conducted and restricting the revenue potential for both established and emerging participants in the market.

Market Trends

The integration of Artificial Intelligence and Machine Learning into genomic data interpretation is fundamentally changing market operations. As sequencing throughput grows, the resulting data volume surpasses manual analysis capacities, requiring automated solutions for variant classification and interpretation. This technology enables laboratories to scale bioinformatic pipelines, shortening turnaround times for complex reports while improving accuracy. The commercial value of this adoption is clear; in a July 2025 survey by NVIDIA titled 'State of AI in Healthcare and Life Sciences: 2025 Trends', over 80% of healthcare and life sciences professionals indicated that AI contributed to revenue growth at their organizations, emphasizing the importance of computational tools for financial performance.

At the same time, a shift toward preventive genomic screening in healthy populations is widening the market beyond symptomatic patients. Health systems are moving from reactive diagnostics to proactive population health management, using large-scale sequencing to detect risk factors for conditions like hereditary cancer and cardiovascular disease before symptoms appear. Major institutional partnerships are supporting this transition to integrate genomic insights into primary care. For example, TriHealth announced in February 2025 a partnership with Helix to launch a precision population health initiative aiming to enroll 100,000 participants over five years, demonstrating the growing scale of preventive genetic data utilization.

Key Market Players

  • 24Genetics SL
  • Prenetics Global Limited
  • Circle DNA
  • TellmeGen
  • 23andMe, Inc.
  • AncestryDNA
  • myDNA Life Australia Pty Ltd.
  • Myriad Genetics, Inc.
  • MapmyGenome
  • MyHeritage Ltd.

Report Scope

In this report, the Global Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genetic Testing Market, By Technology

  • Next Generation Sequencing
  • Array Technology
  • PCR-based Testing

Genetic Testing Market, By Application

  • Ancestry & Ethnicity
  • Traits Screening
  • Genetic Disease Carrier Status
  • New Baby Screening
  • Health & Wellness-Predisposition/Risk/Tendency

Genetic Testing Market, By Product

  • Consumables
  • Equipment
  • Software & Services

Genetic Testing Market, By Channel

  • Online
  • Offline

Genetic Testing Market, By End User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Genetic Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genetic Testing Market.

Available Customizations:

Global Genetic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genetic Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Next Generation Sequencing, Array Technology, PCR-based Testing)
    • 5.2.2. By Application (Ancestry & Ethnicity, Traits Screening, Genetic Disease Carrier Status, New Baby Screening, Health & Wellness-Predisposition/Risk/Tendency)
    • 5.2.3. By Product (Consumables, Equipment, Software & Services)
    • 5.2.4. By Channel (Online, Offline)
    • 5.2.5. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Genetic Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By Product
    • 6.2.4. By Channel
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genetic Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Product
        • 6.3.1.2.4. By Channel
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Genetic Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Product
        • 6.3.2.2.4. By Channel
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Genetic Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Product
        • 6.3.3.2.4. By Channel
        • 6.3.3.2.5. By End User

7. Europe Genetic Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By Product
    • 7.2.4. By Channel
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Genetic Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Product
        • 7.3.1.2.4. By Channel
        • 7.3.1.2.5. By End User
    • 7.3.2. France Genetic Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Product
        • 7.3.2.2.4. By Channel
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Genetic Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Product
        • 7.3.3.2.4. By Channel
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Genetic Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Product
        • 7.3.4.2.4. By Channel
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Genetic Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Product
        • 7.3.5.2.4. By Channel
        • 7.3.5.2.5. By End User

8. Asia Pacific Genetic Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By Product
    • 8.2.4. By Channel
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Genetic Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Product
        • 8.3.1.2.4. By Channel
        • 8.3.1.2.5. By End User
    • 8.3.2. India Genetic Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Product
        • 8.3.2.2.4. By Channel
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Genetic Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Product
        • 8.3.3.2.4. By Channel
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Genetic Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Product
        • 8.3.4.2.4. By Channel
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Genetic Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Product
        • 8.3.5.2.4. By Channel
        • 8.3.5.2.5. By End User

9. Middle East & Africa Genetic Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By Product
    • 9.2.4. By Channel
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Genetic Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Product
        • 9.3.1.2.4. By Channel
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Genetic Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Product
        • 9.3.2.2.4. By Channel
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Genetic Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Product
        • 9.3.3.2.4. By Channel
        • 9.3.3.2.5. By End User

10. South America Genetic Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By Product
    • 10.2.4. By Channel
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Genetic Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Product
        • 10.3.1.2.4. By Channel
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Genetic Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Product
        • 10.3.2.2.4. By Channel
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Genetic Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Product
        • 10.3.3.2.4. By Channel
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Genetic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. 24Genetics SL
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Prenetics Global Limited
  • 15.3. Circle DNA
  • 15.4. TellmeGen
  • 15.5. 23andMe, Inc.
  • 15.6. AncestryDNA
  • 15.7. myDNA Life Australia Pty Ltd.
  • 15.8. Myriad Genetics, Inc.
  • 15.9. MapmyGenome
  • 15.10. MyHeritage Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer